U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07678684) titled 'A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma' on June 07.
Brief Summary: The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Glioma
Adult
Intervention:
DRUG: HF1K16
An investigational drug administered via intravenous (IV) infusion on specified days of a 28-day cycle.
Recruitment Status: NOT_YET_RECRUITIN...